Everolimus precision therapy for the GATOR1‐related epilepsies: A case series
European Journal of Neurology2023Vol. 30(10), pp. 3341–3346
Citations Over TimeTop 10% of 2023 papers
Patrick B. Moloney, Hugh Kearney, Katherine A. Benson, Daniel J. Costello, Gianpiero L. Cavalleri, Kathleen M. Gorman, Bryan J. Lynch, Norman Delanty
Abstract
Our study provides the first human data on the potential benefit of everolimus precision therapy for epilepsy caused by DEPDC5 loss-of-function variants. Further studies are needed to support our findings.
Related Papers
- → Missense variant contribution to USP9X-female syndrome(2020)37 cited
- → G328E and G409E sialin missense mutations similarly impair transport activity, but differentially affect trafficking(2007)11 cited
- → Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital(2018)5 cited
- → Proactive functional classification of all possible missense single-nucleotide variants in KCNQ4(2022)17 cited
- → Recurrent missense variant identified in two unrelated families with MPZL2‐related hearing loss, expanding the variant spectrum associated with DFNB111(2024)